Intranasal Oxytocin Boosts Self-Compassion Imagination in Borderline Personality Disorder Patients

Borderline personality disorder (BPD) is marked by severe emotion dysregulation, interpersonal challenges, and high self-criticism, which often impede engagement with therapeutic practices like compassion-based meditation. Current treatments struggle to fully address these core deficits. Oxytocin, a neuropeptide known to modulate social-affective processes and empathy, has been hypothesized to facilitate specific mechanisms involved in psychotherapy, potentially improving receptivity to compassion training in this vulnerable population.

This pilot study involved 18 individuals diagnosed with Borderline Personality Disorder (BPD). Participants were randomized to receive either intranasal oxytocin (24 IU) or a placebo before engaging in a guided compassion-based meditation practice. This intervention was administered over five weekly sessions. The primary endpoint, compassion practice quality, was assessed at baseline (T1) and at the study's conclusion (T5). Endpoint differences between the oxytocin and placebo groups were analyzed using ANCOVA models, controlling for baseline values.

Compared to the placebo group, participants receiving oxytocin demonstrated significantly higher endpoint scores on the imagination dimension of compassion practice quality. This suggests oxytocin specifically facilitated the ability to engage in imagery processes during meditation. No significant differences were observed for the total compassion practice quality score or its somatic dimension, indicating a targeted effect on cognitive-imaginative aspects rather than overall or physical components. Importantly, no adverse effects related to oxytocin administration were reported, suggesting good tolerability in this cohort. The study highlights oxytocin's potential to modulate specific subjective experiences during compassion-based practices, particularly those involving mental imagery.